Objectives: As reported previously, tear film surface quality (TFSQ) should be considered in contact lens (CL) fitting. This study followed noninvasive keratograph tear film break-up time (NIKBUT) in CL wearers for 12 months to validate its clinical utility in predicting CL performance.
Methods: Fifty-five subjects (M/F=17/38) aged 26±4 years were prescribed silicone hydrogel or hydrogel CLs. The study included baseline measurements without CLs; 2 visits for CL fitting and control; follow-up after 3, 6, and 12 months of CL wear; and postwear visit without CLs. Ocular Surface Disease Index (OSDI), 8-Item Contact Lens Dry Eye Questionnaire (CLDEQ-8), first and mean NIKBUT (F/M-NIKBUT), fluorescein tear film break-up time (FBUT), and ocular surface staining were evaluated.
Results: Post hoc analysis of each pair of visits showed differences between baseline and all CL visits for F-NIKBUT, M-NIKBUT, FBUT, and corneal staining. No difference was reported in symptoms. In addition, differences between baseline and postwear visits were noted in OSDI, M-NIKBUT, FBUT, and corneal staining, with three of the latter parameters showing a downward trend.
Conclusions: No changes in TFSQ and symptoms were reported over 12 months. Introducing NIKBUT as part of routine CL fitting is advised to improve CL fit and predict success.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICL.0000000000000811 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics.
Ophthalmol Ther
January 2025
Santa Barbara Eye Care, Santa Barbara, CA, USA.
Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.
View Article and Find Full Text PDFIn Vitro and In Vivo Visualization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Using Infrared Emissivity.
Cornea
November 2024
Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY.
Purpose: To visualize the behavior of perfluorohexyloctane (PFHO), an eye drop to treat dry eye disease (DED), on the surface of saline in vitro and on the human ocular surface using infrared emissivity.
Methods: Emissivity videos were used to measure the spreading and disappearance rates of PFHO on saline (with and without mucin for spreading rate) and layered over a 125 nm film of meibum on the surface of saline using a TearView camera. Ocular surface emissivity was videoed in a volunteer without DED before and after instillation of 1 drop of PFHO.
Scleral Contact Lens Benefits for Myopic Patients With Regular Corneas: A Prospective Randomized Study.
Eye Contact Lens
November 2024
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Objectives: To evaluate the impact of scleral contact lens (SL) wear on the visual quality and the ocular surface wettability in myopic patients with regular corneas.
Methods: This prospective, randomized, controlled study enrolled a total of 80 myopes with regular corneas. Subjects were randomly allocated to wear SL or rigid corneal lens (RCL) for 3 months.
Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).
Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.
An update on emerging pharmacological treatments for meibomian gland dysfunction.
Expert Opin Pharmacother
January 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!